An Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Latest Information Update: 26 Aug 2025
At a glance
- Drugs SHR 8068 (Primary) ; Adebrelimab; Bevacizumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 08 Aug 2025 Status changed from not yet recruiting to recruiting.
- 28 Jul 2025 New trial record